Mayo Clinic

Center of Innovation for Brain Tumor Therapeutics - Project Description/abstract – Overall the Development of Effective Therapies for Glioblastoma (GBM) Has Been Incredibly Vexing With No New Drug Approvals in Over a Decade. Therapeutic Resistance in Any One Patient With GBM Can Be Related to Multiple Factors Including Extensive Tumor Cell Infiltration Into Adjacent Brain, Molecular Heterogeneity of Tumor Cell Populations, and Heterogeneity of Drug Distribution. in Order to Understand and Overcome These Challenges, We Have Built a Highly Productive, Multi-disciplinary Scientific Team Over the Past Decade With Expertise Spanning Systems Biology, Pharmacology, Tumor Biology, and Animal Models of GBM. in the Proposed U19 Center Application, We Will Integrate This Established Cross-disciplinary Translational Science Team With Physician Scientists in Radiation and Medical Oncology, Neurosurgery and Neuroradiology With a Collective Focus of Translating Novel Therapeutic Strategies Into Highly Effective Therapies for Patients With GBM. Impaired DDR Enables the Genomic Instability Required for Tumorigenesis, and Differences in DDR Functionality Between Tumor and Normal Tissue Provides the Fundamental Rationale for Using Radiation Therapy or Genotoxic Drugs as Anti-cancer Therapies. Additional Targeted Pharmacologic Disruption of DDR in Tumors Can Markedly Enhance the Efficacy of These Cytotoxic Therapies and Widen the Therapeutic Window. in This Context, We Have Collaborated Extensively With Multiple Pharmaceutical Companies to Evaluate Various Small Molecule DDR Inhibitors and Have Developed Significant Preliminary Data Demonstrating Profound Combinatorial Efficacy for These Drugs When Combined With Radiation or Alkylating Chemotherapy Routinely Used for GBM. Thus, the Initial Focus for Our Center Is to Optimize the Clinical Deployment of DDR Inhibitors in Combination With Cytotoxic Therapies for GBM. a Pharmacology Core Will Support Both Pharmacokinetic (PK) and Pharmacodynamic (PD) Evaluations in Animal Models and Human Samples, and Our Therapy Evaluation Core Will Support Both Pre-clinical and Clinical Testing of Novel Therapeutic Strategies. the Project and Core Teams Will Work in Close Collaboration to Accomplish the Goals of the Center, and This Collaborative Effort Within the Center and Across the Broader Glioma Therapeutics Network (GTN) Will Be Coordinated by the Administrative Core.